Clinical trials: Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.
- Trial name
- NCT02960555
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
High Risk Smoldering Multiple Myeloma
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
This is an open-label, single arm, multicenter, interventional study with Dara-VRD followed by cilta-cel in high-risk smoldering multiple myeloma (SMM) patients.
- Trial name
- CAR-HiRiSMM (NCT06574126)
- Testing
- Group 1: Dara-VRD followed by apheresis and cilta-cel infusion, Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- PETHEMA Foundation
High Risk Smoldering Multiple Myeloma
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
The purpose of this research study is to test whether the drug ibrutinib (trademark name: IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who currently have smoldering myeloma.
- Trial name
- NCT02943473
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.
- Trial name
- NCT02697383
- Testing
- Ixazomib (MLN9708), Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Screening to Improve Survival in AL Amyloidosis
The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS.
- Trial name
- NCT04615572
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tufts Medical Center
Monoclonal Gammopathy, Smoldering Multiple Myeloma
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
- Trial name
- NCT03236428
- Testing
- Daratumumab
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma, Multiple Myeloma Progression
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and…
- Conditions
- Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
- Trial name
- NCT06644625
- Testing
- Blood draw for the laboratory assessment
- Where
- United States
- Volunteers
- 1,665 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Pre-cancerous Lymphoproliferative Disorders
Oxford Pre-cancerous Lymphoproliferative Disorders Study
OxPLoreD is an observational cohort study to identify clinical, genomic and immunological predictive markers of progression to malignant disease.
- Trial name
- OxPLoreD (NCT04023747)
- Where
- 17 sites in United Kingdom
- Volunteers
- 574 people
- Sponsor
- University of Oxford
Multiple Myeloma
Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
Multiple myeloma cells are dependent on calcium (Ca2+) for their function. Specifically, Ca2+ is required for the function of the endoplasmic reticulum in which proteins, including immunoglobulins, are folded prior to their…
- Trial name
- NCT01965834
- Testing
- Fenofibrate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Monoclonal Gammopathy of Undetermined Significance, Smoldering Myeloma
Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
The purpose of this study is to describe DNA copy number variations and gene expression profiles of bone marrow plasma cells of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
- Trial name
- GENOMGUS (NCT01079429)
- Testing
- Genetic study of DNA copies
- Where
- 27 sites in France
- Volunteers
- 1,200 people
- Sponsor
- Rennes University Hospital
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease…
- Trial name
- NCT02726750
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Indolent Plasma Cell Myeloma, Plasma Cell Myeloma
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
This partially randomized phase I/II trial studies the side effects and best dose of anakinra when given together with lenalidomide and dexamethasone in treating patients with early stage multiple myeloma.
- Conditions
- Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT02492750
- Testing
- Anakinra, Dexamethasone, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
Background: Multiple myeloma is a type of cancer that affects white blood cells and has a poor long-term survival rate. Two other types of cancer, monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma…
- Trial name
- NCT01109407
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma precursor disease or newly…
- Conditions
- Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Trial name
- FAST-M (NCT07446777)
- Testing
- Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Miami
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
This randomized phase II trial studies how well celecoxib works in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT00099047
- Testing
- celecoxib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Smoldering Multiple Myeloma
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation.
- Trial name
- NCT02415413
- Testing
- carfilzomib, Lenalidomide, Dexamethasone
- Where
- 16 sites in Spain
- Volunteers
- 90 people
- Sponsor
- PETHEMA Foundation
Smoldering Multiple Myeloma
A Phase II Study of BI-505 in Smoldering Multiple Myeloma
The purpose of this study is to investigate the effect of BI-505 on tumor burden in patients diagnosed with smoldering multiple myeloma.
- Trial name
- NCT01838369
- Testing
- BI-505
- Where
- Sweden
- Volunteers
- 4 people
- Sponsor
- BioInvent International AB
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma.
- Conditions
- High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT05469893
- Testing
- Teclistamab, Lenalidomide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Irene Ghobrial, MD
Multiple Myeloma
Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma
Purpose: The purpose of this study is to see if TBL 12, which is a blend of Sea Cucumber, Sea Sponge, Shark Fin, and Sea Urchin (animals that live in the Pacific Ocean) as well as Sargassum (a plant that lives in the Pacific…
- Trial name
- NCT01096810
- Testing
- TBL 12
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jagannath, Sundar, M.D.
Plasma Cell Dyscrasias
The Indiana Myeloma Registry
This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research
- Trial name
- NCT03616483
- Testing
- This is a non-interventional trial
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Indiana University